Drug Discovery, Economics, and Therapeutics: Comprehensive Notes

Drug Discovery, Development, and Economics: Comprehensive Notes

• General trajectory of drug development

  • Preclinical and clinical phases; discovery in the preclinical/pre-recorded stage can take a long time in the precordial part (as per transcript).
  • Most drugs fail somewhere along the development process, often during preclinical, but failures also occur in clinical trials.
  • The oft-cited figure that a new drug costs about a billion dollars to develop is misleading: the cost is inflated by failures; only a fraction of candidates succeed, and the costs of failures are recouped by the drugs that do succeed.
  • Drug companies sometimes pursue repurposing: using an FDA-approved drug for a new, different indication; this can be faster and cheaper since toxicology and safety data already exist, but toxicology remains expensive and lengthy.
  • Safety monitoring is ongoing through trials and post-market, with genetic diversity across populations causing variable adverse events (e.g., allergies) in people who have not previously taken the drug.

• Repurposed drugs

  • Repurposed drugs are FDA-approved for a different purpose; the idea is to find new uses for existing drugs.
  • Example concept: inhibiting a viral enzyme to slow replication and reduce viral load (antiviral repurposing context is discussed).
  • The audience is not required to memorize the specific repurposed drugs listed; focus is on the mechanism and potential for repurposing.

• Cost of development and economic rationale

  • Drug companies are often criticized for high pricing, given their large profits; however, industry economics are complex.
  • The “cost to develop a drug” is not simply the listed price; it includes recouping costs from successful drugs to cover the high failure rate.
  • The top-selling drugs during the COVID era saw substantial investment in antibody therapies.

• Phase progression and safety monitoring

  • Phase II: safety and efficacy in a larger population; ongoing safety monitoring due to genetic diversity and differences in patient backgrounds.
  • Phase III: large-scale trials to confirm efficacy and safety in hundreds to thousands (sometimes tens of thousands) of patients to support FDA approval.
  • FDA approval hinges on demonstrating drug effectiveness in a large population and overall safety.
  • Antiviral repurposing example noted: inhibiting an enzyme to slow viral replication; effectiveness is limited but may reduce viral load.

• Drug company economics and market dynamics

  • The argument that drugs cost a lot to develop is tied to the need to fund failures and recoup investments through successful products.
  • Big pharmaceutical companies (e.g., Pfizer) are for-profit entities; debates surround how they price drugs.
  • A significant portion of revenue comes from lines of therapy with large, ongoing demand (chronic diseases).

• Revenue focus by disease category

  • Oncology (cancer) is a major money-making category; cancers are increasingly treated as chronic conditions with longer patient survival, generating sustained revenue.
  • Chronic conditions like diabetes and cardiovascular diseases (including hypertension, anticoagulants) also generate substantial revenue; vaccines (pandemics) yield high upfront investment but variable long-term revenue.
  • Acute conditions (e.g., antibiotics) historically generate limited long-term revenue because treatment duration is short and stewardship limits broad deployment.
  • Immunosuppressants and anticoagulants have been profitable, though many are off-patent and facing generic competition.
  • Neurodegeneration (e.g., Alzheimer’s, Parkinson’s) is a wide-open but challenging market due to complex biology and the need for early diagnosis/biomarkers.

• Drug patents, generics, and biosimilars

  • Patent protection: typically 20 years from the filing date, not from the market launch; a substantial portion of that time is spent in R&D and trials, meaning effective market exclusivity can be shorter.
  • When a patent expires, generics (chemical copies) can enter the market and drive down price; biosimilars are analogous copies of biologics but are not identical and require evidence of similar safety and efficacy.
  • Generics are exact chemical copies; biosimilars are highly similar but not identical; both require FDA approval.
  • Brand-name drugs often maintain higher pricing until generics/biosimilars capture market share; doctors and payers may favor generics to reduce costs.
  • A brand-name drug may lose its protection when the patent expires, opening the market to generics; biosimilars follow a similar but distinct path.

• Patent lifecycle and market strategy

  • Drug companies argue for a short window to recoup R&D investments; they also spend on marketing to sustain brand value.
  • Brand-name drugs rely on patents and marketing to maintain market dominance; once generics/biosimilars enter, prices tend to fall.
  • The existence of brand name comfort and consumer preference supports continued sales despite generic competition.

• Disease areas with high profitability and lifecycle considerations

  • Oncology is currently highly lucrative due to chronicization of some cancers and improved survival.
  • Diabetes and other chronic conditions provide long-term payer obligations; type 1 is chronic; type 2 can be managed or reversed in some cases but is generally long-term.
  • Vaccines, antiviral drugs (pandemics), immunosuppressants, and anticoagulants have contributed to revenue streams, with varying durations of exclusivity and competition.
  • Some classic categories (statins, antihypertensives, some anticoagulants) have faced patent expirations and generics, shrinking margins for new entrants.
  • Neurodegenerative diseases remain a challenging, high-need area with many failures and limited successful therapies; early detection and biomarkers are crucial to therapy effectiveness.

• neglected and underfunded areas in drug development

  • Drug companies have historically under-invested in tropical neglected diseases (e.g., malaria) and acute infections due to lower profitability.
  • Antibiotics have a dual problem: they are essential but have limited long-term revenue potential due to stewardship and the desire to slow resistance development; this creates a market failure incentive problem for new antibiotics.
  • Rare diseases were historically neglected due to small patient populations; the Orphan Drug Act (1983) created economic incentives to spur development for these conditions.

• Orphan Drug Act and incentives

  • Orphan Drug Act (1983) provided incentives to develop treatments for rare diseases:
  • Tax credits for research expenses
  • Grants and research support
  • Seven years of market exclusivity
  • Fee waivers for FDA processes
  • Impact: the number of drugs approved for rare diseases increased dramatically from about 38 drugs approved pre-Act to over 730 drugs developed for rare diseases; however, many rare diseases still lack FDA-approved therapies.
  • Controversies: orphan drugs can be very expensive, with average annual costs around $123{,}000$ per patient in some cases, raising questions about affordability and access.

• Priority Review Voucher and tropical diseases

  • FDA Priority Review Voucher program (2007): develop drugs for neglected tropical diseases (later extended to rare pediatric diseases) to reward developers with a voucher for expedited FDA review of another drug.
  • Vouchers can be sold; some have fetched very high prices (e.g., $67{,}000{,}000$ and even up to $350{,}000{,}000$ in reported cases).
  • The voucher mechanism provides a secondary market incentive to push research for neglected diseases, though overall impact on tropical disease drug development has been mixed.

• Antibiotics: resistance, economics, and stewardship

  • Rising drug resistance presents a major global health threat; bacteria evolve and acquire mechanisms such as efflux pumps and drug-inactivating enzymes, and resistance genes spread between bacteria.
  • CDC estimates (as cited): about $2.8 imes 10^{6}$ people develop resistant infections, with about $3.5 imes 10^{4}$ deaths; projections suggested up to $1.0 imes 10^{7}$ infections by 2015 if trends continued.
  • Antibacterial drug development faces poor profitability due to stewardship: new antibiotics are deployed slowly to preserve effectiveness, which reduces sales but improves long-term utility; this creates a tension between public health goals and industry incentives.
  • In 2019, cancer research spending was about $9.7 imes 10^{9}$ (dollars), whereas antibiotic R&D funding was only about $1.32 imes 10^{8}$, illustrating stark funding disparities.
  • The sustainability challenge for new antibiotics has been estimated to require annual revenue of around $3.0 imes 10^{8}$ to be viable; stewardship policies can undermine long-term sales, creating policy tension.
  • Policy response: ongoing discussions about legislative incentives (e.g., the PASTEUR Act) to encourage antibiotic development; at the time of the transcript, no final approved legislation had passed.
  • Practical implication: without new incentives, the pipeline for antibiotics remains inadequate amid rising resistance.

• Rare diseases and market incentives: a deeper look

  • Pre-Act landscape: few drugs existed for rare diseases; there are about 10,000 rare diseases, affecting limited patient populations (definition: fewer than 200{,}000 people in the U.S.).
  • Orphan Drug Act outcomes: large increase in therapies for rare diseases, though affordability remains a concern for patients and payers.
  • The need for ongoing policy engagement to expand access and affordability for rare-disease therapies.

• Important numbers and formulas (quick reference)

  • Drug development cost myth vs reality: costs recouped across successful drugs due to failures elsewhere.
  • Industry average success rate: $0.041$ (4.1%).
  • Alzheimer's disease trial success rate: $0.005$ (0.5%).
  • Patent term: $T_{ ext{patent}} = 20 ext{ years from filing date}$.
  • Orphan Drug Act exclusivity: $E = 7 ext{ years}$.
  • Rare disease definition: affects fewer than $2 imes 10^{5}$ people.
  • Antibiotic resistance projections (CDC): $2.8 imes 10^{6}$ infections, $3.5 imes 10^{4}$ deaths; projection of up to $1 imes 10^{7}$ infections by 2015.
  • Cancer R&D spending (2019): $9.7 imes 10^{9} ext{ USD}$.
  • Antibiotics R&D spend (2019): $1.32 imes 10^{8} ext{ USD}$.
  • High-revenue example: Pfizer’s Lyrica (pregabalin) revenue around $23.6 ext{ billion}$ by early 2018; patent expiry noted around 2019, leading to generic entry.
  • Priority Review Voucher values: reported examples include $6.7 imes 10^{7}$ and up to $3.5 imes 10^{8}$ USD for transferred vouchers.
  • Serum and signaling concepts (exam prep context) involve numbers like timeframes and percentages in questions, not fixed biological constants.

• Drug discovery process: key concepts and targets

  • Most drugs are small molecules that bind to protein pockets; identifying druggable pockets is central to early drug design.
  • G protein-coupled receptor (GPCR) signaling basics covered in exam prep:
  • First messengers: extracellular signals (e.g., hormones, neurotransmitters) that initiate signaling between cells.
  • Second messengers: intracellular amplifiers (e.g., cAMP, IP3, DAG, Ca2+, cGMP).
  • G protein activation steps:
  • Ligand binds to GPCR, causing conformational change.
  • The G protein exchanges GDP for GTP on the α-subunit, causing dissociation of Gα from Gβγ and leading to downstream signaling.
  • Desensitization mechanism: receptor phosphorylation by kinases followed by arrestin binding reduces receptor-G protein coupling and prevents over-activation.
  • NO-cGMP pathway: nitric oxide activates soluble guanylyl cyclase, converting GTP to the second messenger $ext{cGMP}$, which mediates smooth muscle relaxation and other processes.
  • IP3/DAG pathway: phospholipase C hydrolyzes PIP2 to generate IP3 (which releases Ca2+ from ER stores) and DAG (which activates PKC).
  • Phosphodiesterase 5 (PDE5) role: breaks down $ext{cGMP}$; inhibitors (e.g., sildenafil/Viagra) prevent this breakdown, acting as an on-switch for erections in the penile tissue by sustaining $ext{cGMP}$ levels.
  • Kinase signaling: kinases phosphorylate target proteins to alter function; PKG is a kinase that phosphorylates substrates but does not produce second messengers.
  • Practically, exam prep emphasizes knowing which components are part of on-switch vs off-switch mechanisms.

• Concrete clinical and pharmacological examples discussed

  • Lyrica (pregabalin): a GABA analogue with multiple indications (e.g., neuropathic pain); Pfizer patent from 2001; high revenue (≈$23.6 ext{B}$ by 2018) followed by generic entry after patent expiry (2019).
  • Statins (e.g., Lipitor, Crestor): historically top-selling cholesterol-lowering drugs; many are off-patent and generics now, increasing competition for new cholesterol-lowering therapies.
  • Clopidogrel off-patent; development of newer antiplatelet agents to outperform older therapies remains challenging.

• Ethical, political, and practical implications

  • Profit motive in drug development vs public health needs: balancing access, affordability, and innovation incentives.
  • Legislation like the Orphan Drug Act and the PASTEUR Act (or related proposals) aims to incentivize development in under-served areas (rare diseases, antibiotics) but faces political hurdles and criticism over pricing and access.
  • Antibiotic stewardship underscores a paradox: you want to conserve antibiotic effectiveness by limiting use, but this reduces sales incentives for pharma companies to invest in new antibiotics.
  • Global health considerations: while the transcript focuses on the US/EU landscape, multinational drug companies operate globally; policy differences can influence R&D incentives and access elsewhere.

• Exam strategy and study tips (as reflected in the transcript)

  • Expect highly specific, mechanism-based questions on signaling pathways (e.g., GPCR activation steps, desensitization, first vs second messengers).
  • Be prepared to identify which components are part of on-switch vs off-switch signaling pathways (e.g., PDE5 inhibition as an off-switch blocker, NO/cGMP as a second messenger pathway).
  • Practice with signaling diagrams and memorize key players (NO, soluble guanylate cyclase, cGMP, IP3, Ca2+, PKG, PKC, G proteins, arrestin).
  • Understand the economic concepts linked to the biology (patent life, exclusivity, generics, biosimilars, rare diseases incentives, antimicrobial incentives).

• Brief synthesis: why these topics matter for exams and real-world policy

  • Drug discovery and development are constrained by biology, safety, efficacy, and economics; the success rate is low (roughly a few percent overall), making the economics of failures critical.
  • Patents and exclusivity drive the balance between incentivizing innovation and enabling patient access via generics/biosimilars.
  • Addressing neglected areas (tropical diseases, antibiotics) requires policy interventions to align public health goals with industry incentives, especially given rising antimicrobial resistance.
  • Real-world drug development involves navigating clinical trial design, safety monitoring across diverse populations, and ethical considerations around affordability and access.